Tissue injury in neutrophilic inflammation

Inflammation Research

Volumn 46, Issue 10, 1997, Pages 382-391

  Dallegri, F ^a   Ottonello, L ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Anti inflammatory drugs; Inflammation; Neutrophils; Oxidants; Proteinases

Indexed keywords

ANTIOXIDANT; CORTICOSTEROID; CYCLIC AMP DEPENDENT PROTEIN KINASE; L SELECTIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEINASE INHIBITOR; SELECTIN; SUPEROXIDE;

BACTERIAL INFECTION; CELL ADHESION; CELL GRANULE; CELL INTERACTION; CELL MIGRATION; HUMAN; INFLAMMATION; NEUTROPHIL; NONHUMAN; OXIDATION; PHENOTYPE; PROTEIN DEGRADATION; REVIEW; TISSUE INJURY; VASCULAR ENDOTHELIUM;

ANTI-INFLAMMATORY AGENTS; CELL ADHESION; CHEMOTAXIS, LEUKOCYTE; ENDOPEPTIDASES; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION; NEUTROPHILS; OXIDANTS;

EID: 0030691102     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000110050208     Document Type: Review

References (130)

1. Malech HL, Gallin JI. Neutrophils in human diseases. N Engl J Med 1987;317:687-94.
2. Styrt B. The role of phagocytes in non-infectious diseases. In: Klempner MS, Styrt B, Ho J, editors. Phagocytes and disease. Dordrecht: Kluwer 1989:145-69.
3. Babior BM. Oxidants from phagocytes: Agents of defence and destruction. Blood 1984;64:959-66.
4. Hamers MN, Roos D. Oxidative stress in human neutrophilic granulocytes: Host defence and self-defence. In: Sies H, editor. Oxidative stress. London: Academic Press, 1985:351-81.
5. Henson PM, Johnston RB. Tissue injury in inflammation: Oxidants, proteinases and cationic proteins. J Clin Invest 1987;79:669-74.
6. Weiss SJ. Tissue destruction by neutrophils. N Engl J Med 1989;320:365-76.
7. Carlos TM, Harlan JM. Leukocyte-endothelial adhesion molecules. Blood 1994;84:2068-101.
8. Cronstein BN, Weissmann G. The adhesion molecules of inflammation. Arthritis Rheum 1993;36:147-57.
9. Bevilacqua M, Nelson RM. Selectins. J Clin Invest 1993; 91:379-87.
10. Albelda SM, Smith CW, Ward PA. Adhesion molecules and inflammatory injury. FASEB J 1994;8:504-12.
11. Lasky L, Rosen SD. The selectins: Carbohydrate-binding adhesion molecules of immune system. In: Gallin JI, Goldstein IM, Snyderman R, editors. Inflammation: basic principles and clinical correlates. New York: Raven Press, 1992:407-19.
12. Philipps ML, Schwartz BR, Etzioni A, Bayer R, Ochs HD, Paulson JC, et al. Neutrophil adhesion in leukocyte adhesion deficiency syndrome type 2. J Clin Invest 1995;96:2898-906.
13. Von Adrian UH, Berger EM, Ramezani L, Chambers JD, Ochs HD, Harlan JM, et al. In vivo behaviours of neutrophils from two patients with distinct inherited leukocyte adhesion deficiency syndrome. J Clin Invest 1993;91:2893-7.
14. Kishimoto TK, Anderson DC. The role of integrins in inflammation. In: Gallin JI, Golstein IM, Snyderman R, editors. Inflammation: basic principles and clinical correlates. New York: Raven Press, 1992:353-406.
15. Pardi R. Inside-out and outside-in mechanisms in leukocyte adhesion. Fund Clin Immunol 1994;2:135-46.
16. Zimmerman GA, Prescott SM, McIntyre TM. Platelet-activating factor. In: Gallin JI, Goldstein IM, Snyderman R, editors. Inflammation: basic principles and clinical correlates. New York: Raven Press, 1992:149-76.
17. Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB J 1992;6:3051-64.
18. Kubes P, Suzuki M, Granger DN. Little oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 1991;88:4651-5.
19. Baggiolini M, Walz A, Kunkel SL. Neutrophil-activating peptide-1/interleukin-8, a novel cytokine that activates neutrophils. J Immunol 1989;84:1045-9.
20. Ben-Baruch A, Michiel DF, Oppenheim JJ. Signals and receptors involved in recruitment of inflammatory cells. J Biol Chem 1995;270:1703-6.
21. Rossi RA, Hellewell PG. Mechanisms of neutrophil accumulation in tissues. In: Hellewell PG, Williams TJ, editors. Immunopharmacology of neutrophils. London: Academic Press, 1994:223-43.
22. Owen CA, Campbell MA, Boudekes SS, Campbell EJ. Inducible binding of bioactive cathepsin G to the cell surface of neutrophils. J Immunol 1995;155:5803-10.
23. Owen CA, Campbell MA, Sannes PL, Boudekes SS, Campbell EJ. Cell surface-bound elastase and cathepsin G on human neutrophils: A novel, non-oxidative mechanism by which neutrophils focus and preserve catalytic activity of serine proteinases. J Cell Biol 1995;131:775-9.
24. Pollanen J, Saksela O, Salonen E, Andreasen P, Nielsen L, Dano K, et al. Distinct localizations of urokinase-type plasminogen activator and its type I inhibitor under cultured human fibroblasts and sarcoma cells. J Cell Biol 1987;104:1085-96.
25. Plow EF, Freaney DE, Plescia J, Miles LA. The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type. J Cell Biol 1986;103:2411-20.
26. Bazzoni F, Cassatella MA, Rossi F, Ceska M, Dewald B, Baggiolini M. Phagocytosing neutrophils produce and release high amounts of the neutrophil-activating peptide 1/interleukin 8. J Exp Med 1991;173:771-4.
27. Cassatella MA, Bazzoni F, Ceska M, Dewald B, Baggiolini M, Berton G. IL-8 production by human polymorphonuclear leukocytes. The chemoattractant formyl-methionyl-leucyl-phenylalanine induces the gene expression and release of IL-8 through a pertussin toxin-sensitive pathway. J Immunol 1992; 148:3216-20.
28. Lam BK, Austen KF. Leukotrienes: Biosynthesis, release and actions. In: Gallin JI, Goldstein IM, Snyderman R, editors. Inflammation: Basic principles and clinical correlates. New York: Raven Press, 1992:139-47.
29. Borregaard N, Lollike K, Kjeldesen L, Sengelov H, Bastholm L, Nielsen MH, et al. Human neutrophil granules and secretory vesicles. Eur J Haematol 1993;51:187-98.
30. Sengelov H. Secretory vesicles. Eur J Haematol 1996:57 Suppl 58.
31. Pabst MG. Priming of neutrophils. In: Hellewell PG, Williams TJ, editors. Immunopharmacology of neutrophils. London: Academic Press, 1994:195-221.
32. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of lipolysaccharide (LPS) and LPS-binding protein. Science 1990;249:1431-3.
33. Troelstra A, Giepmans BNG, Van Kessel KPM, Lichenstein HS, Verhoef J, Van Strijp JAG. Dual effects of soluble CD14 on LPS priming of neutrophils. J Leuk Biol 1997;61:173-8.
34. Wright SD, Ramos RA, Hermanowski-Vosatka A, Rockwell P, Detmers PA. Activation of the adhesive capcaity of CR3 on neutrophils by endotoxin: Dependence on lipolysaccharide binding protein and CD14. J Exp Med 1991;173:1281-6.
35. Wright SD, Meyer BC. Phorbol esters cause sequential activation and deactivation of complement receptors on polymorphonuclear leukocytes. J Immunol 1986;136:1759-64.
36. 2, Mac-1). Indirect effects of an ARG-GLY-ASP (RGD) sequence. J Immunol 1993;151: 3324-36.
37. de Haas M, Vossebeld PMJ, von dem Borne AEGK, Roos D. Fcγ receptors of phagocytes. J Lab Clin Med 1995;126:330-41.
38. Hulett MD, Hogart PM. Molecular basis of Fc receptor function. Adv Immunol 1994;57:1-127.
39. Santana C, Noris G, Espinoza B, Ortega E. Protein tyrosine phosphorylation in leukocyte activation through receptors for IgG. J Leuk Biol 1996;60:433-40.
40. 2. In: Hellewell PG, Williams TJ, editors. Immunopharmacology of neutrophils. London: Academic Press, 1994:159-93.
41. Sehgal G, Zhang K, Todd III RF, Boxer LA, Petty HR. Lectin-like inhibition of immune complex receptor-mediated stimulation of neutrophils. J Immunol 1993;150:4571-80.
42. II and tyrosine phosphorylation. J Leuk Biol 1994;125:1407-16.
43. Sassone-Corsi P. Goals for signal transduction pathways: linking up with transcriptional regulation. EMBO J 1994;13:4717-28.
44. Nishizuka Y. Protein kinase C and lipid signalling for sustained cellular responses. FASEB J 1995;69:484-96.
45. Quilliam LA, Mueller H, Bohl BP, Prossnitz V, Sklar LA, Der CJ, et al. Rapl A is a substrate for cyclic AMP-dependent protein kinase in human neutrophils. J Immunol 1991;147: 1628-35.
46. Ottonello L, Morone MP, Dapino P, Dallegri F. Tumor necrosis factor alpha-induced oxidative burst in neutrophils adherent to fibronectin: effects of cyclic AMP-elevating agents. Br J Haematol 1995;91:566-70.
47. Ottonello L, Morone MP, Dapino P, Dallegri F. Cyclic AMP-elevating agents down-regulate the oxidative burst induced by granulocyte-macrophage colony stimulating factor (GM-CSF) in adherent neutrophils. Clin Exp Immunol 1995;101:502-6.
48. Mueller H, Montoya B, Sklar LA. Reversal of inhibitory pathways in neutrophils by protein kinase antagonist: a rational approach to the restoration of depressed cell function? J Leuk Biol 1992;52:400-6.
49. Haslett C. Resolution of acute inflammation and the role of apoptosis in the tissue fate of granulocytes. Clin Sci 1992;83:639-48.
50. Colotta F, Re F, Polentarutti N, Sozzani S, Mantovani A. Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. Blood 1992;80:2012-20.
51. Pericle F, Liu JH, Diaz JI, Blanchard DK, Wei S, Forni G, et al. Interleukin-2 prevention of apoptosis in human neutrophils. Eur J Immunol 1994;24:440-4.
52. Savill J. Macrophage recognition of senescent neutrophils. Clin Science 1992;83:649-59.
53. Groselin E, Wardwell K, Rigby W, Guyre P. Induction of MHC class II on human polymorphonuclear neutrophils by granulocyte/macrophage colony-stimulating factor. IFN-γ, and IL-3. J Immunol 1993;151:1482-90.
54. Reali E, Guerrini R, Moretti S, Spisani S, Lanza F, Tomatis R, et al. Polymorphonuclear neutrophils pulsed with synthetic peptides efficiently activated memory cytotoxic T lymphocytes. J Leuk Biol 1996;60:207-13.
55. Tiku K, Tiku ML, Skosey JL. Interleukin-1 production by human polymorphonuclear neutrophils. J Immunol 1986;136: 3677-85.
56. Cassatella MA, Bazzoni F, D'Andrea A, Tronchin M, Ceska M, De Gironcoli M, et al. Studies on the production of proinflammatory cytokines and on the modulation of the gene expression for some NADPH oxidase components by phagocytosing human neutrophils. Fund Clin Immunol 1993;1:99-106.
57. Visser MCM, Day WA, Winterbourn CC. Neutrophils adherent to a nonphagocytosable surface (Glomerular basement membrane) produce oxidants only at site of attachment. Blood 1985;66:161-6.
58. Karnovsky ML, Bolis L. Phagocytosis - past and future. New York: Academic Press, 1982:1-592.
59. Babior BM, Kipnes RS, Curnutte JT. Biological defense mechanisms. The production by leukocytes of superoxide, a potential bactericidial agent. J Clin Invest 1984;5:717-24.
60. Borregaard N, Heiple JM, Simons ER, Clark RA. Subcellular localization of the b-cytochrome component of human neutrophil oxidase: translocation during activation. J Cell Biol 1983;97: 52-61.
61. Winterbourn CC. Neutrophil oxidants: Production and reactions. In: Das DK, Essma WB, editors. Oxygen radicals: systemic events and disease processes. Basel: Karger, 1990:31-70.
62. Wheeler MA, Smith SD, Garcia-Cardena G, Nathan CF, Weiss RM, Sessa WC. Bacterial infection induces nitric oxide synthase in human neutrophils. J Clin Invest 1997;94:110-6.
63. Schmidt HHHW, Walter U. NO at work. Cell 1994;78:919-25.
64. Test ST, Weiss SJ. The generation and utilization of chlorinated oxidants by human neutrophils. Adv Free Rad Biol Med 1986;2:91-116.
65. Dallegri F, Ballestrero A, Frumento G, Patrone F. Augmentation of neutrophil-mediated erythrocyte lysis by cells derived in vitro from human monocytes. Blood 1987;70:743-9.
66. Dallegri F, Patrone F, Ballestrero A, Frumento G, Sacchetti C. Inhibition of neutrophil cytolysin production by target cells. Blood 1986;67:1265-72.
67. Weiss SJ, Klein R, Slivka A, Wei M. Chlorination of taurine by human neutrophils. Evidence for hypochlorous acid generation. J Clin Invest 1982;70:598-607.
68. Winterbourn CC. Myeloperoxidase as an effective inhibitor of hydroxyl radical production. Implications for the oxidative reactions of neutrophils. J Clin Invest 1986;78:545-50.
69. Clark RA. Extracellular effects of myeloperoxidase-hydrogen peroxide-halide system. In: Weissmann G, editor. Advances in inflammation research, vol 5. New York: Raven Press, 1983:107-46.
70. Jackson JH, Cochrane CG. Leukocyte-induced tissue injury. In: Curnutte JT, editor. Phagocytic defects: Abnormalities of the respiratory burst. Philadelphia: Saunders, 1988:317-34.
71. Dallegri F, Goretti R, Ballestrero A, Ottonello L, Patrone F. Neutrophil induced depletion of adenosine triphosphate in target cells: evidence for a hypochlorous acid-mediated process. J Lab Clin Med 1988;112:765-72.
72. Bernofsky C. Nucleotide chloramines and neutrophil-mediated cytotoxicity. FASEB J 1991;5:295-300.
73. Zaslow MC, Clark RA, Stone PJ, Calore JD, Snider GL, Franzblau C. Human neutrophil elastase does not bind to alpha-1-protease inhibitor that has been exposed to activated human neutrophils. Am Rev Respir Dis 1983;128:434-9.
74. Ossanna PJ, Test ST, Matheson NR, Regiani S, Weiss SJ. Oxidative regulation of neutrophil elastase-alpha-1-proteinase inhibitor interaction. J Clin Invest 1986;77:1939-51.
75. Carrell RW. α1-Antitrypsin: Molecular pathology, leukocytes and tissue damage. J Clin Invest 1986;78:1427-31.
76. Desrochers PE, Weiss SJ. Proteolytic inactivation of alpha-1-proteinase inhibitor by a neutrophil metalloproteinase. J Clin Invest 1988;81:1646-50.
77. Ottonello L, Dapino P, Scirocco M, Dallegri F, Sacchetti C. Proteolytic inactivation of alpha-1-antitrypsin by human neutrophils. Involvement of multiple and interlinked cell responses to phagocytosable targets. Eur J Clin Invest 1994;24:42-9.
78. Crystal RG. α-1-antitrypsin deliciency, emphysema and liver disease. Genetic basis and strategies of therapy. J Clin Invest 1990;85:1343-52.
79. Travis J. Structure, function and control of neutrophil proteinase. Am J Med 1988;84:37-42.
80. Janoff A. Elastases and emphysema. Current assessment of the protease-antiprotease hypothesis. Am Rev Respir Dis 1985;132: 417-33.
81. Cochrane CG, Spragg R, Revak S. Pathogenesis of the adult respiratory distress syndrome. J Clin Invest 1983;71:754-61.
82. Abbink JJ, Kamp AM, Nuijens JH, Swaak TJG, Hack CE. Proteolytic inactivation of α1-antitrypsin and chimotrypsin by neutrophils in arthritic joints. Arthritis Rheum 1993;36:168-80.
83. Vered M, Dearing R, Janoff A. A new elastase inhibitor from Streptococcus pneumoniae protects against acute lung injury induced by neutrophil granules. Am Rev Respir Dis 1985;131: 131-3.
84. Ross L, Hassman F, Malony L. Inhibition of Molt-4-endothelial adherence by synthetic peptides from the sequence of ICAM-1. J Biol Chem 1992;267:8537-43.
85. Nelson RM, Dolich S, Aruffo A, Cecconi O, Bevilacqua MP. Higher-affinity oligosaccaride ligands for E-selectins. J Clin Invest 1993;91:1157-66.
86. Burch RM, Weitzberg M, Blok N, Nuhlhauser R, Martin D, Farmer SG, et al. N-fluorenyl-9-methoxycarbonyl amino acids, a class of anti-inflammatory agents with a different mechanism of action. Proc Natl Acad Sci USA 1991;88:355-9.
87. Bennett CF. Inhibition of endothelial cell adhesion molecule expression with antisense oligonucleotides. J Immunol 1994;152: 3530-40.
88. Sokoloski JA, Sartorelli AC, Rosen CA, Narayanan R. Antisense oligonucleotides to the p65 subunit of NF-κB block CD11b expression and alter adhesion properties of differentiated HL-60 granulocytes. Blood 1993;82:625-32.
89. Hebert CA, Chuntharapai A, Smith M, Colby T, Kim J, Horuk R. Partial functional mapping of the human interleukin-8 type A receptor. J Biol Chem 1993;268:18549-53.
90. Bullard DC, Qin L, Lorenzo I, Quinlin WM, Doyle NA, Bosse R, et al. P-selectin/ICAM-1 double mutant mice show a complete block in peritoneal emigration of neutrophils. J Clin Invest 1995;92:1782-8.
91. Doerschuk CM, Winn RK, Coxson HO, English D, Hogg JC. CD18-dependent and independent mechanisms of neutrophil adherence in the pulmonary and systemic microvasculature of rabbits. J Immunol 1990;144:2327-33.
92. Rot A, Hub E, Middleton J, Pons F, Rabeck C, Thierer K, et al. Some aspects of IL-8 pathophysiology III: chemokine interaction with endothelial cells. J Leuk Biol 1996;59:39-44.
93. Cronstein BN, Molad Y, Reibman J, Balakhane E, Levin RI, Weissmann G. Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. J Clin Invest 1995;96:994-1002.
94. Ahramson SB, Weissmann G. The mechanisms of action of nonsteroidal antiinflammatory drugs. Arthritis Rheum 1989;32: 1-9.
95. Goldstein RA, Bowen DL, Fauci AS. Adrenal Corticosteroids. In: Gallin JI, Goldstein IM, Snyderman R, editors. Inflammation: basic principles and clinical correlates. New York: Raven Press, 1992:1061-81.
96. Perianin A, Giroud JP, Hakin J. Differential in vivo effects of indomethacin, ibuprofen and flurbiprofen on oxygen-dependent killing activities of neutrophils elicited by acute non-immune inflammation in the rat. Inflammation 1988;2:181-9.
97. Ip M, Lowas DA, Shaw J, Burnett D, Stockley RA. Effect of nonsteroidal anti-inflammatory drugs on neutrophil chemotaxis. An in vitro and in vivo study. Brit J Rheumatol 1990;29:363-7.
98. Sordelli DD, Cerquetti MC, El-Tawil G. Ibuprofen modifies the inflammatory response of murine lung to Pseudomonas aeruginosa. Eur J Resp Dis 1985;67:118-27.
99. Rinaldo JE, Pennock B. Effect of ibuprofen on endotoxin-induced alveolitis: Biphasic dose response and dissociation between inflammation and hypoxemia. Am J Med Sci 1986; 291:29-38.
100. Perianin A, Gougerot-Pocidalo MA, Giroud JP, Hakin J. Diclofenac binding to human polymorphonuclear neutrophils: effect on respiratory burst and N-formylated peptide binding. Biochem Pharmacol 1987;36:2609-15.
101. Skubitz KM, Hammerschmidt DE. Effects of ibuprofen on chemotactic peptide-receptor binding and granulocyte response. Biochem Pharmacol 1986;35:3349-54.
102. Blackburn WD, Heck LW, Loose LD, Eskra JD, Corty IJ. Inhibition of 5-lipoxygenase product formation and polymorphonuclear cell degranulation by tenidap sodium in patients with rheumatoid arthritis. Arthritis Rheum 1991;34:204-10.
103. 4 in activated neutrophils by nimesulide due to an elevation of intracellular cyclic adenosine monophosphate. Arzneim Forsch/Drug Res 1995;45:1110-4.
104. Crowell RE, VanEpps DE. Nonsteroidal antiinflammatory agents inhibit upregulation of CD11b, CD11c and CD35 in neutrophils stimulated by formyl-methionine-leucine-phenylalanine. Inflammation 1990;14:163-71.
105. Verhoeven AJ, Tool ATJ, Kuipers JW, Roos D. Nimesulide inhibits platelet-activating factor synthesis in activated human neutrophils. Drugs 1993;46:52-8.
106. Chang D, Baptiste P, Schur PH. The effect of antirheumatic drugs on interleukin-1 (IL-1) activity and IL-1 and IL-1 inhibitor production by monocytes. J Rheumatol 1990;17:1148-75.
107. Sipe JD, Bartle LA, Loose LD. Modification of proinflammatory cytokine production by the antirheumatic agents tenidap and naproxen. A possible correlate with clinical acute phase response. J Immunol 1992;148:480-4.
108. Rosenstein ED, Kunicka J, Kramer N, Goldstein G. Modification of cytokine production by piroxicam. J Rheumatol 1994;21: 901-4.
109. Kaplan HB, Edelson HS, Korchak HM, Given WP, Abramson S, Weissmann G. Effect of non-steroidal anti-inflammatory agents on human neutrophil function in vitro and in vivo. Biochem Pharmacol 1984;33:371-8.
110. Ottonello L, Dapino P, Pastorino G, Dallegri F. Inhibition of the neutrophil oxidative response induced by the oral administration of nimesulide in normal volunteers. J Clin Lab Immunol 1993b;37:91-6.
111. Neal TM, Visser MCM, Winterbourn CC. Inhibition by non-steroidal anti-inflammatory drugs of superoxide production and granule enzyme release by polymorphonuclear leukocytes stimulated with immune complexes or formyl-methionyl-leucyl-phenylalamine. Biochem Pharmacol 1987;36:2511-7.
112. Torphy TJ, Undem BJ. Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. Thorax 1991;46: 512-23.
113. Cronstein BN, Eberle MA, Gruber HE, Levin RI. Methotrexate inhibits neutrophil function by stimulating adenosine release from the connective tissue cells. Proc Natl Acad Sci USA 1991;88:2441-5.
114. Kammer GM. Adenosine: Emerging role as an immunomodifying agent. J Lab Clin Med 1987;110:255-6.
115. Antonysamy MA, Moticka EJ, Ramkumar V. Adenosine acts as an endogenous modulator of IL-2-dependent proliferation of cytotoxic T lymphocytes. J Immunol 1995;155:2813-21.
116. Sekut L, Yarnall D, Stimpson A, Noel LS, Bateman-Fite R, Clark RL, et al. Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation. Clin Exp Immunol 1995;100:126-32.
117. Anaya JM, Espinoza LR. Phosphodiesterase inhibitor pentoxifylline: An anti-inflammatory/immunomodulatory drug potentially useful in some rheumatic diseases. J Rheumatol 1995;22: 595-9.
118. Bevilacqua M, Vago T, Baldi G, Renesto E, Dallegri F, Norbiato G. Nimesulide decreases superoxide production by inhibiting phosphodiesterase type IV. Eur J Pharmacol 1994;268: 415-23.
119. Dallegri F, Ottonello L, Dapino P, Sacchetti C. Effect of non-steroidal anti-inflammatory drugs on the neutrophil promoted inactivation of alpha-1-proteinase inhibitor. J Rheumatol 1992; 19:419-23.
120. Ottonello L, Dapino P, Dallegri F. Inactivation of alpha-1-proteinase inhibitor by neutrophil metalloproteinases. Crucial role of the myeloperoxidase system and effects of the anti-inflammatory drug nimesulide. Respiration 1993a;60:32-7.
121. Ottonello L, Dapino P, Scirocco M, Balbi A, Bevilacqua M, Dallegri F. Sulphonamides as anti-inflammatory agents: old drugs for new therapeutic strategies in neutrophilic inflammation? Clin Science 1995;88:331-6.
122. Meyers S. The place of oral 5-aminosalicylic acid in the therapy of ulcerative colitis. Am J Gastroenterol 1988;83:64-7.
123. Ottonello L, Dapino P, Pastorino G, Vitale E, Dallegri F. The drug 5-aminosalicylic acid rescues α1-proteinase inhibitor from the neutrophil oxidative inactivation. Digestion 1992;51:140-5.
124. Stroncek DF, Vercellotti GM, Huh PW, Jacob HJ. Neutrophil oxidants inactivate alpha-1-protease inhibitor and promote PMN-mediated detachment of cultured endothelium. Artheriosclerosis 1986;6:332-40.
125. Nakamura H, Yoshimura K, McElvaney, Crystal RG. Neutrophil elastase in respiratory lining fluid of individuals with cystic fibrosis; interleukin-8 gene expression in a human bronchial epithelial cell line. J Clin Invest 1992;89:1478-84.
126. Crystal RG. Oxidants and respiratory tract epithelial injury: Pathogenesis and strategies for therapeutic intervention. Am J Med 1991;91:39-44.
127. Heffner JE, Repine JE. Pulmonary strategies of antioxidant defense. Am Rev Respir Dis 1989;140:531-54.
128. Bernard GR. N-acetylcysteine in experimental and clinical acute lung injury. Am J Med 1991;91:54-9.
129. Suter PM, Domenighetti G, Schaller M, Laverriere M, Ritz R, Perret C. N-acetylcysteine enhances recovery from acute lung injury in man. Chest 1994;105:190-4.
130. Blackwell TS, Blackwell TR, Holden EP, Christman BM, Christman JW. In vivo antioxidant treatment suppresses nuclear factor-κB activation and neutrophilic lung inflammation. J Immunol 1996;157:1630-7.